Zevra Therapeutics (NASDAQ:ZVRA) Receives “Buy” Rating from HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $20.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 122.97% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a report on Tuesday, September 24th. They set an “outperform” rating and a $17.00 price target for the company. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price target for the company. Roth Mkm increased their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Finally, Maxim Group increased their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $21.00.

Zevra Therapeutics Stock Performance

ZVRA opened at $8.97 on Wednesday. The company has a market cap of $478.78 million, a price-to-earnings ratio of -4.55 and a beta of 1.93. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The company’s 50 day moving average is $8.06 and its 200 day moving average is $6.54. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.21.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The business had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the previous year, the firm earned ($0.40) EPS. On average, equities research analysts predict that Zevra Therapeutics will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ZVRA. International Assets Investment Management LLC grew its holdings in shares of Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock worth $48,000 after buying an additional 5,940 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Zevra Therapeutics during the first quarter worth $64,000. Hunter Associates Investment Management LLC purchased a new position in Zevra Therapeutics in the 3rd quarter valued at $92,000. XTX Topco Ltd acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $94,000. Finally, Intech Investment Management LLC purchased a new position in Zevra Therapeutics during the 3rd quarter worth $95,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.